Viriom Obtains First Market Approval of Elsulfavirine (Elpida®) for Treatment of HIV-1 Infection in Russia

- Viriom's 20mg Daily Elsulfavirine (Elpida®)-based Regimen Demonstrated High Efficacy in High and Low HIV Titer Patients with Significantly Improved Safety Compared with 600mg Efavirenz-based Regimens -

SAN DIEGO, July 25, 2017 /PRNewswire/ -- Viriom, Inc (Viriom), a San Diego-based biotech company, today announced that on June 30, 2017 the Russian Ministry of Health (MoH) granted an approval to Viriom's non-nucleoside reverse transcriptase inhibitor (NNRTI) elsulfavirine (brand name Elpida®). Non-nucleoside reverse transcriptase inhibitors block HIV replication. The labeling requested was for the "treatment of HIV-1 infection in combination with other antiretroviral medicines." Viriom's first product on the market, elsulfavirine is a new-generation, potentially the best in class prodrug NNRTI approved for the treatment of the HIV-1 virus due to its potency, pharmacokinetic properties and favorable resistance profile.

The Russian MoH based its approval of elsulfavirine on the results of a 48-week multicenter comparative clinical study conducted in 12 clinical centers.  The results presented to the MoH confirmed an efficacy non-inferior to efavirenz (currently used as a first-line treatment of HIV-1); elsulfavirine demonstrated equally superior efficacy in patients with a high or low HIV titer at baseline.  Overall, it was 2-4 times safer and better tolerated than efavirenz including a lower frequency of adverse events related to the CNS, with no allergic reactions or skin rash observed. Elsulfavirine demonstrated a higher genetic barrier to the development of resistant drug mutations. Elsulfavirine is available as a 20mg capsule to be taken orally. Viriom is continuing the development of fixed dose combinations of elsulfavirine for the treatment of the HIV-1 infection and working towards market registration of elsulfavirine and fixed dose combinations globally. Viriom is also developing long-acting, injectable formulations of parent drug VM1500A for treatment and prevention of the HIV-1 infection based on the unique pharmacokinetic and pharmacodynamic properties of elsulfavirine demonstrated in clinical trials to date.

About Viriom: 
Viriom focuses on the treatment, prophylaxis, and eradication of infectious diseases globally. Viriom is developing and commercializing the most innovative and affordable solutions to radically expand global access to antiviral treatments. Viriom's broad, proprietary, and partnered pipeline covers therapeutic, prophylactic, and curative medicines for HIV and viral hepatitis. Learn more at

Media Contact:
Ronald Demuth, CFO, Viriom

Safe Harbor Statement

This document may contain forward-looking statements. Such forward-looking statements are characterized by future or conditional verbs such as "may," "will," "expect," "intend," "anticipate," "believe," "estimate" and "continue" or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information. Such statements are only predictions and our actual results may differ materially from those anticipated in these forward-looking statements. We believe that it is important to publicly communicate future expectations. However, there may be events in the future that we are not able to accurately predict or control. Factors that may cause such differences include, but are not limited to, the uncertainties associated with product development, the market for our products, the risks associated with dependence upon key personnel and the need for additional financing. We do not assume any obligation to update forward-looking statements as circumstances change. The information in this document is not targeted at the residents of any particular country or jurisdiction and is not intended for distribution to, or use by, any person in any jurisdiction or country where such distribution or use would be contrary to local law or regulation. The future expectations, estimations, anticipated events, results, milestones, events, operating and financial information contained in the company's financial projections and all other areas of this document are for illustrative purposes only and are based upon hypothetical assumptions and events over which the company has only partial or no control. All information about future events (projections) were developed by the company's management and are based upon a variety of assumptions with or without benefit of an operating history. The projections are included solely to provide information concerning the company's estimates of future operating results based on these assumptions and, although the company believes that these assumptions are reasonable, they may be incomplete or incorrect, and unanticipated events and circumstances may occur. Actual results will vary from the projections, and these variations may be material and adverse. The projections should be read in conjunction with the assumptions upon which the projections are based. No representation or warranty of any kind is or can be made with respect to the accuracy or completeness of, and no representation or warranty should be inferred from our projections or the assumptions underlying them.